International Consensus Opinions in OpsoclonusMyoclonus-Ataxia Syndrome

Hot
G Updated
International Consensus Opinions in OpsoclonusMyoclonus-Ataxia Syndrome

Course Description

The objectives of this symposium on opsoclonus-myoclonusataxia syndrome (OMAS) are to provide participants with up-todate consensus opinions from a collaborative international OMAS study group. Attendees will learn current epidemiology, diagnostic criteria, biological mechanisms of disease, optimal treatment, and long-term outcomes.

Learning Objectives 1. Explain cardinal presenting features, ratings scales, and the clinical course of opsoclonusmyoclonus-ataxia syndrome (OMAS). 2. Apply common evaluation and treatment practices for patients with OMAS.

Impact Statements

  1. The recognition and initial evaluation of children with opsoclonus-myoclonus-ataxia syndrome.
  2. The use of immunomodulatory agents in the early course of and long-term follow-up of opsoclonus-myoclonus-ataxia syndrome.

Organizer
Tim Lotze, MD
Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA

Cardinal Presenting Features, Rating Scales, and the Clinical Course of OpsoclonusMyoclonus-Ataxia Syndrome
Ming Lim, MD, PhD
Evelina London Children’s Hospital, King’s Health Partners Academic Health Science Centre, London, United Kingdom

Recognized Etiologies and Emerging Biomarkers in Opsoclonus-Myoclonus- Ataxia Syndrome
Russell Dale, MRCP, PhD
Children’s Hospital at Westmead, University of Sydney, Sydney, NSW, Australia

Consensus Recommendations for the Evaluation and Treatment of Opsoclonus-MyoclonusAtaxia Syndrome
Mark Gorman, MD
Boston Children’s Hospital, Boston, Massachusetts, USA

Short and Long-term Neurodevelopmental Outcomes in Opsoclonus-Myoclonus- Ataxia Syndrome
Wendy G. Mitchell MD
Keck School of Medicine, Children’s Hospital Los Angeles, Los Angeles, California, USA

Viewer Review

No viewer reviews
Already have an account? or Create an account

Join Our Newsletter